Opioid-sparing Strategies in Alloplastic Breast Reconstruction: A Systematic Review

Dustin T. Crystal, MD*
Ahmed M. S. Ibrahim, MD, PhD†
Louise L. Blankensteijn, MD†
Nicholas G. Cuccolo, MD‡
Darya Kazei, MD†
Helen S. Zikovsky, BA†
Bernard T. Lee, MD, MPH, MBA†
Samuel J. Lin, MD, MBA†

Abstract

Introduction: Pain and discomfort are frequently experienced following mastectomy with concomitant breast implant- or tissue expander-based alloplastic breast reconstruction (AlBR). Unfortunately, postoperative opioids have decreased efficacy in AlBR, short-term complication profiles, and are fraught by long-term dependence. This systematic review aims to identify opioid-sparing pain management strategies in AlBR.

Methods: A systematic literature search of MEDLINE, Embase, Web of Science, and Cochrane Central Register was performed in September 2018. PRISMA guidelines were followed, and the review was prospectively registered in PROSPERO (CRD42018107911). The search identified 1184 articles. Inclusion criteria were defined as patients 18 years or older undergoing AlBR.

Results: Fourteen articles were identified assessing opioid-sparing strategies in AlBR. This literature included articles evaluating enhanced recovery protocols (two), intercostal blocks (two), paravertebral blocks (four), liposomal bupivacaine (three), diclofenac (one), and local anesthesia infusion pumps (two). The literature included five randomized trials and nine cohort studies. Study characteristics, bias (low to high risk), and reporting outcomes were extensively heterogeneous between articles. Qualitative analysis suggests reduced opioid utilization in enhanced recovery after surgery (ERAS) pathways, paravertebral blocks, and use of liposomal bupivacaine.

Conclusions: A variety of opioid-sparing strategies are described for pain management in AlBR. Multimodal analgesia should be provided via ERAS pathways as they appear to reduce pain and spare opioid use. Targeted paravertebral blocks and liposomal bupivacaine field blocks appear to be beneficial in sparing opioids and should be considered as essential components of ERAS protocols. Additional prospective, randomized trials are necessary to delineate the efficacy of other studied modalities. (Plast Reconstr Surg Glob Open 2021;9:e3932; doi: 10.1097/GOX.0000000000003932; Published online 16 November 2021.)

INTRODUCTION

Breast cancer is estimated to affect over 260,000 individuals in the United States annually, making it the most common carcinoma in women. Therapeutic strategies rely on ablative surgery, chemoradiation, and subsequent reconstruction. Restoring form, function, and quality of life, postmastectomy implant- or tissue expander (TE)-based breast reconstruction (collectively, “alloplastic”) remains the most commonly performed reconstructive modality.

Patients who undergo immediate alloplastic breast reconstruction (AlBR) tend to experience more postoperative pain than those undergoing mastectomy without reconstruction. This occurs despite high opioid use, suggesting poor opioid efficacy in this patient population. Significant postoperative pain impairs recovery, contributes to poor patient satisfaction, and is correlated to increased rates of chronic postmastectomy pain. There is a subsequent need to definitively and effectively treat postmastectomy pain through multimodal approaches which involve the overall reduction or minimization of opioid narcotics.

Disclosure: The authors have no financial interest to declare in relation to the content of this article.
Excessive postoperative opioid use is not without morbidity, and its use has effects of associated nausea, vomiting, altered mentation, and respiratory depression. More troubling, opioid overprescription, as is observed in a number of plastic surgery procedures, can lead to opioid dependence. Subsequent opioid use, misuse, and overdose seen in the current nationwide epidemic has contributed to a decline in the US life expectancy for two consecutive years.

These conclusions necessitate judicious prescribing practices and promote implementation of alternatives to opioid-based pain management. Subsequent evaluation of opioid use in plastic surgery highlights a new era of patient safety and practice progression. To derive the methodological clarity and efficacy of various pain protocols, we aim to systematically review the literature and identify opioid-sparing pain management strategies in AlBR.

**METHODS**

**Study Design**

This study protocol was prospectively registered with PROSPERO, an international register of systematic reviews (Study ID: CRD42018107911). The systematic review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement guidelines.

**Study Criteria**

Inclusion criteria were defined as patients 18 years or older undergoing breast reconstruction. Only cases of AlBR (TE or implants) were included. Patients undergoing nonreconstructive breast surgery (i.e., mastectomy alone, oncoplastic reduction, and augmentation) were excluded. Interventions assessed included opioid-sparing pain management techniques. The primary outcome was defined as mean morphine equivalent units utilized. Secondary outcomes included time to ambulation, hospital length of stay (HLOS), hospital expenditures/costs, patient reported pain-scales, opioid-related adverse events, postoperative complications, and postoperative opioid use.

No time limit was placed on published articles. Only English-language literature was included. Randomized or nonrandomized controlled trials and cohort studies were included. Studies with less than 10 patients were excluded. Animal studies were excluded. “Gray literature” was assessed and included if methodology was accessible and scientifically sound.

**Search Strategy**

The search was conducted on September 17, 2018, by an experienced research librarian at the Countway Medical Library at the Harvard Medical School. The following four databases were searched: MEDLINE (Pubmed/Ovid), Embase (Elsevier), Web of Science (Clarivate Analytics), and Cochrane Central Register of Controlled Trials (Wiley). Our full-text search strategy is accessible at PROSPERO.

**Takeaways**

**Question:** What approaches or medical means can surgeons utilize to reduce the number of opioid narcotics that patients require for pain following breast reconstruction?

**Findings:** Multimodal analgesia should be provided via ERAS pathways including targeted paravertebral blocks and liposomal bupivacaine field blocks, as these techniques appear to treat pain effectively and reduce postoperative opioid consumption.

**Meaning:** Postoperative opioid usage can be reduced by employing specific forms of multimodal pain control. This will likely translate into better patient satisfaction and reduce overall opioid consumption.

**Data Extraction, Bias Assessment, and Statistical Analysis**

Extracted articles were imported into Covidence. Duplicate references were removed (n = 412). Titles and abstracts were screened by two authors (D.T.C. and L.L.B.). Split decisions were made by an independent reviewer (N.G.C.). Final article selection and full-text analysis was performed by two reviewers (D.T.C. and A.M.S.I.). Study-level bias was assessed utilizing the risk of bias in nonrandomized studies of interventions (ROBINS-I) tool. Assessments of study bias were dependent on confounding, bias in intervention classification, bias from intervention deviations, bias in missing data and selective result reporting, and bias in outcome measurements. Missing data are highlighted in the discussion as appropriate. Due to the heterogenous nature of study and outcome measures, meta-analysis and sensitivity-analyses were not performed. Mean outcome values were compared based on article test statistics.

**RESULTS**

**Articles Identified**

A branching-logic diagram of search results and article processing is depicted in Figure 1. Fourteen articles meeting defined criteria were included in this review (Table 1).

**“Enhanced Recovery after Surgery” Protocols**

Chiu et al describe implementation of an enhanced recovery after surgery (ERAS) protocol (Table 2) for mastectomy with submuscular AlBR in a proposed 23-hour hospitalization. Their intention-to-treat analysis included 276 pre-ERAS (traditional management) and 96 ERAS patients. ERAS implementation increased preoperative acetaminophen, gabapentin, scopolamine, and regional anesthesia utilization. The total mean morphine equivalent units utilized were statistically reduced in the ERAS cohort, (111.4 ERAS versus 168.3 pre-ERAS) with statistically significant reductions in morphine equivalents used throughout other hospital settings [intraoperative, postanesthesia care unit (PACU), and on the wards]. On average, ERAS patients had lower maximal pain scores. Multivariate regression demonstrated decreased opioid
use in the ERAS cohort. ERAS patients demonstrated significant reductions in lorazepam use (−10%) and postoperative nausea/vomiting (−23%). No statistical change in HLOS was observed in the setting of 23-hour admission.

Dumestre et al.28 evaluated 29 patients in an outpatient model ERAS pathway undergoing immediate, subpectoral AIBR. ERAS patients were compared to 29 controls and 11 patients operated on during a “transition” period before full ERAS implementation. HLOS was reduced among ERAS patients: 1.6 nights among controls compared to less than 24 hours for ERAS patients. Compared to the transition cohort, the ERAS cohort described statistically significant improvements in “severe pain,” “nausea,” and “sleep” defined by a recovery questionnaire. There were no cohort differences in reported postoperative complications. Follow-up communication with ERAS patients were “overall positive” without comparison to other cohorts.

Paravertebral Blocks

A nonblinded, randomized control trial by Wolf et al.29 described patients undergoing AIBR randomized to ropivacaine paravertebral blocks (PVBs, n = 35) or no PVB (n = 39) with standardized nausea prophylaxis, opioids, and pain assessments. A statistical reduction in opioid consumption was observed in the PVB cohort (108 versus 246 fentanyl equivalents). Those receiving PVB had significantly less pain at 0–1 and 3–6 hours, in addition to reduced 24-hour “worst” pain ratings (1.50 ± 3.22 PVB versus 2.39 ± 3.49 control). PVB patients consumed statistically fewer antiemetics tablets (0.71 versus 2.1) despite nonstatistically different rates of nausea. Patients in the PVB cohort received promethazine, dexamethasone, and ondansetron postoperatively for nausea prophylaxis, but dosages and frequency of administration were not noted.

Additional articles analyzing PVBs in AIBR were retrospective in design.31–33 Table 3 illustrates principal findings. Fahy et al.31 described outcomes of mastectomy with bupivacaine PVB in 232 patients (55% with AIBR), compared to 294 patients without PVB (51% with AIBR). Although HLOS, opioid use, and antiemetic use were statistically reduced in the total cohort, subgroup analysis demonstrated that opioid reductions were only significant in cases of bilateral reconstruction (48.8 ± 14.4 mg PVB versus 63.1 ± 20.2 mg non-PVB). Reductions in antiemetic use were not observed for bilateral reconstruction, and neither opioid nor antiemetic use were reduced in unilateral reconstructions. Coopey et al.32 reported a faster transition to oral opioid agents in 190 PVB patients...
undergoing mastectomy with AIBR compared to 154 controls (Table 3).Comparatively, Aufforth et al 36 evaluated 59 patients undergoing mastectomy and AIBR, 45 received bupivacaine PVBs and 14 were controls. They found significant reductions in morphine equivalent use on the subgroup analysis of reconstruction (25.3 mg PVB versus 42.8 mg non-PVB), but this did not persist among the total cohort’s (317 patients) opioid use. No cases of pneumothorax were noted in the manuscripts.

**Intercostal Blocks**

In their randomized controlled trial, Lanier et al 37 described intercostal and pectoral blocks on patients undergoing immediate AIBR randomized to bupivacaine and dexamethasone injections (n = 23) or placebo saline injections (n = 22). Pain regimens were standardized patient-controlled anesthesia (PCA) transitioning to per os (PO) agents. There was a nonsignificant decrease in morphine equivalent use among nerve block patients (92 units treatment versus 114 units control, P = 0.31). Despite nerve block patients tending toward reduced PACU pain scores, there were no statistical pain score differences between cohorts. Discharge quality of recovery questionnaires did not differ.

Shah et al 38 described retrospective results of bupivacaine thoracic intercostal blocks (ICBs) in 89 immediate AIBR patients compared to 43 patients undergoing AIBR without ICB. Morphine requirements were reduced in patients who received ICBs for bilateral (5.15 mg ICB versus 12.68 mg non-ICB) and unilateral (2.80 mg ICB versus 8.17 mg non-ICB) reconstructions. ICB patients trended (P > 0.05) toward less oral oxycodone consumption. In bilateral reconstructions, statistically decreased HLOS (1.87 ICB versus 2.32 days non-ICB) and diazepam consumption (22.24 mg ICB versus 31.13 mg non-ICB) were noted in ICB patients. No difference in antiemetics use was observed. A pneumothorax occurred in one ICB patient.

**Liposomal Bupivacaine**

Motakef et al 35 presented randomized trial data for liposomal bupivacaine (LB) among 24 patients undergoing TE or direct-to-implant AIBR. Twelve patients received LB, whereas 12 received bupivacaine field blocks. Cohorts were well matched and excluded chronic pain patients. Postoperatively, patients received standing diazepam and as needed opioids and ondansetron. Motakef et al 35 found significant reductions in benzodiazepine use and morphine equivalents utilized among LB patients (0.76 versus 1.43 morphine equivalent dosing/hr). The LB cohort required significantly shorter HLOS (29.8 versus 46.7 hours) and reduced hospital expenditures ($10,828 versus $18,632). Hospital expenditures were largely based on HLOS. Average pain scores were similar with no significant adverse events.

Abdelsattar et al 36 retrospectively reviewed patients who underwent unilateral or bilateral mastectomy with TE AIBR. Fifty-three patients received a preoperative ultrasound-guided PVB compared to 44 who received local, intraoperative LB. Patients were discharged once ambulating on PO analgesics. On multivariable analysis, opioid use in the recovery room was significantly lower in the LB group compared to the PVB group (mean ± SD; 9.4 ± 16.4 LB versus 24.8 ± 23.9 PVB morphine equivalents; P = 0.03), as were day of surgery pain scores via a numeric rating scale (3.2 LB versus 4.2 PVB; score range 0–10, P = 0.05). However, HLOS, antiemetic consumption, and total opioid consumption were not different.

### Table 1. Characteristics of Studies Meeting Inclusion Criteria

| Study | Study Type (LOE) | Intervention | Primary Outcome(s) | Bias |
|-------|-----------------|--------------|--------------------|------|
| Chiu et al 27 | Retrospective (2) | ERAS protocol | Total perioperative opioid consumption, oral morphine equivalents | Low-to-moderate risk |
| Dimestre et al 28 | Prospective cohort with retrospective arm (2) | ERAS protocol | Length of stay and proof of concept safety | High-to-severe risk |
| Shah et al 29 | Retrospective (2) | Thoracic intercostal blocks vs placebo saline injections | Postoperative pain, antiemetic use, and HLOS | Moderate risk |
| Lanier et al 30 | Randomized controlled trial (1) | Intercostal and pectoral nerve blocks vs placebo saline injections | Global 40-item Quality of Recovery Questionnaire, pain scores, opioid consumption | Low risk |
| Wolf et al 31 | Randomized controlled trial (1) | PVB vs no PVB | Postoperative pain and opioid consumption | Low risk |
| Fahy et al 32 | Retrospective (2) | PVB | Hospital discharge <36 hrs, PACU LOS, opioid consumption, and antiemetic use | High risk |
| Coopey et al 33 | Retrospective (2) | PVB vs PVB | Opioid consumption | Moderate risk |
| Aufforth et al 34 | Retrospective (2) | LB compared PVB | Oral morphine equivalents consumed, pain scores, HLOS, time to first opioid | Moderate-to-high risk |
| Motakef et al 35 | Randomized controlled trial (1) | LB vs bupivacaine blocks | Opioid and benzodiazepine consumption, and HLOS | Low-to-moderate risk |
| Butz et al 36 | Retrospective (2) | LB | Mean morphine equivalents, and HLOS | High-to-severe risk |
| Legeby et al 37 | Randomized controlled trial (1) | Diclofenac suppository vs placebo suppository | Postoperative pain (rest and dynamic) and opioid consumption | Low-to-moderate risk |
| Lu and Fine 38 | Prospective cohort with retrospective arm (2) | Bupivacaine IP | Postoperative PACU pain; opioid consumption | Moderate risk |
| Strazisar et al 39 | Randomized (1) | Levobupivacaine pump compared to piritramide infusion | Opioid consumption, antiemetic requirements, and sedation | High risk |

LOE, level of evidence; LOS, length of stay.
Butz et al. retrospectively evaluated 90 AlBR patients receiving either a bupivacaine pain pump (n = 30), LB field blocks (n = 30), or a control arm (n = 30) without regional anesthesia or a single intraoperative dose of bupivacaine or lidocaine. All patients received a PCA on postoperative day (POD) 0 and were transitioned to oral hydrocodone/acetaminophen by POD 1. There were no significant differences in antiemetic or opioid use (1137 ± 508 MME LB, 1275 ± 580 MME pain pump, 1205 ± 500 control; P = 0.605). The LB cohort had statistically lower subjective pain scores at 4-, 8-, 12-, 16-, and 24-hour time points. A significant association between LB and the same-day discharge was observed.

Diclofenac
Legeby et al. evaluated AlBR patients blinded and randomized to receive 50mg diclofenac (n = 25) or placebo suppository (n = 23) every 8 hours. Perioperative medica- tion s were standardized per Table 4. The diclofenac cohort utilized significantly fewer opioids within the first 6 postoperative hours (16.9 versus 25.6mg of opioids); however, no difference was observed during later time points (total use: 46.4 versus 53.3mg of opioids, P = 0.092). In the first 20 postoperative hours, results controlling for axillary procedures and mastectomy laterality demonstrated reduced rest pain in the diclofenac cohort (analog scale 0–10, median: 2.1 diclofenac versus 3.0 placebo). No differences were observed in nausea and/or drowsiness. Diclofenac was a predictor of perioperative blood loss; however, no patients required reoperation for bleeding. One placebo patient required naloxone for opioid-induced hypoventilation.

Local Anesthetic IPs
Lu and Fine described local anesthetic infusion pumps (IPs) in 35 patients receiving TE reconstruction with a catheter infusing 5.0–7.0 cc/hr of 0.25% bupiva- caine compared to 39 controls. There was significantly less PACU hydromorphone consumption by IP patients (0.8 ± 0.8 and 1.4 ± 0.7mg). Subgroup analysis of inpatients demonstrated a similar reduction in oral hydrocodone/acetaminophen consumption (2.1 ± 2.9 and 4.2 ± 3.2 tablets, P = 0.02). In the PACU, the authors noted statistically reduced pain scores in IP patients (2.0 ± 1.9 versus 4.1 ± 1.2). There were no significant differences in complications or HLOS.
Strazisar et al.39 also evaluated local infusion in AlBR, randomizing 30 patients to subpectoral 0.25% levobupivacaine IP compared to 30 controls receiving continuous IV infusion containing 30 mg piirritramide, 20 mg metoclopramide, and 2.5 g metamizole. Patients were transitioned to PO diclofenac or paracetamol/tramadol after 24 hours. The IP cohort used significantly fewer opioids (9.8 versus 29.4 mg piirritramide) and had reduced incidence of nausea (measured through metoclopramide use, 11.0 versus 24.3 mg) within the first 24 hours. There were no significant differences in tramadol/paracetamol and diclofenac use or complication rates. Strazisar et al.39 did not disclose the HLOS for each cohort. However, they noted that the combined mean HLOS was 5.3 days, and that HLOS did not vary when the two cohorts were compared.

**DISCUSSION**

AlBR is frequently performed following mastectomy in the immediate setting. The previous literature has demonstrated considerable postoperative pain and prolonged hospitalization, which may worsen postreconstruction quality of life.26,41 Opioid treatment falls short with questionable efficacy and significant side-effects. Our systematic review aimed to identify opioid-sparing strategies in AlBR. To systematically review each article, we have divided our discussion into an evaluation of individual studies and summary statements for six opioid-sparing strategies.

**ERAS Protocols**

Implementation of ERAS protocols in AlBR (Table 2) offers patients a transition to outpatient care through multimodal analgesia. Chiu et al.47 demonstrated reduced postoperative opioid consumption, whereas Dumestre et al.32 demonstrated improved postoperative satisfaction. Despite commendable studies, limitations exist. Chiu et al reported reduced protocol adherence, evidenced by only moderate increases in total IV anesthesia (8% pre-ERAS, to 33% ERAS) and dexamethasone administration (18% pre-ERAS, to 53% ERAS). Moreover, analgesic characteristics of pre-ERAS patients (ie, PRN versus around-the-clock administration) were not documented and preclude judicious comparison. Comparatively, Dumestre et al’s study is limited by exclusion of patients with ASA class greater than 2, limited demographic information, and neither denoting nor controlling for prior opioid use or chronic pain syndromes (CPS). The study does not report total

| Table 3. Summary of Retrospective Assessments of Paravertebral Blocks in Alloplastic Breast Reconstruction |
| Study | PVB Type | HLOS | Nausea/ Antimetic Requirements | Opioid Requirements | Pain Scores | Multivariable Analysis |
|-------|----------|------|-----------------------------|---------------------|-------------|-----------------------|
| Aufforth et al.38 | 0.25% bupivacaine injection at T1–T6 | Significantly increased in PVB cohort (0.83 vs 0.58 d) | No significant difference in postoperative nausea between cohorts | No significant difference in morphine equivalents between total cohorts | N/A | Not performed |
| Coopey et al.35 | 0.5% bupivacaine injection at T1 | Incidence of nausea was reduced in the PVB cohort (42.8% vs 54.7%) | Time of conversion from intravenous to oral opioids was shorter in the PVB cohort (15 vs 20 hrs) | N/A | Not performed |
| Fahy et al.36† | 0.25%–0.5% bupivacaine injection at T1, T3, T5 | HLOS <36 hrs significantly lower in the PVB cohort (55.2% vs 42.2%) | Opioid use was significantly lower in the PVB cohort (40.1 ± 15.2 vs 47.6 ± 17.7) | †No statistical difference in pain scores on POD0 (4.9 ± 2.4) vs 4.9 ± 2.4 | Controlling for procedure year, age, and surgery; HLOS was no longer significantly different; differences in antemetic and opioid use persisted |

Significant implies $P < 0.05$.

*Persisted on subgroup analysis of tissue expander recipients and direct-to-implant patients.
†Data reported for overall cohort. Discussion of reconstruction subgroup analysis in-text.
‡No statistical difference observed between cohorts with respect to time spent within the PACU.

---

**Table 4. Randomized Control Trial Standardized Medication Profile**

| Therapy | Preoperative | Intraoperative | Postoperative |
|---------|--------------|---------------|--------------|
| Anesthesia | GA; 50mL 0.5% lidocaine infused into breasts before mastectomy | GA; 50mL 0.5% lidocaine infused into breasts before mastectomy | 1000mg PO, every 8 hrs |
| Paracetamol | 1000mg PO, 1 hr before surgery | Fentanyl (and sevoflurane) for anesthesia maintenance | Intravenous PCA delivering morphine or ketobemidone |
| Opioids | 1 hr before surgery | | |
| Thromboprophylaxis | Low molecular weight heparin, 1 hr before surgery | | |
| Diclofenac | Randomization; 50mg diclofenac every 8 hrs. Treatment starts 1 hr before surgery and continues for a total of 3 d. | | |
opiod consumption, but interestingly included standing administration of preoperative oxycodone with postoperative administration of up to 12 PRN oxycodone tablets (no dosing or administration reported) and subsequent PRN tramadol-acetaminophen (no dosing noted, 1–2 tablets every 3–4 hours). Such oxycodone reporting does not provide clarity in opioid administration and detracts from study evaluation. The reporting per-breast complications and subjective stratification of complication categories, without reporting aggregate complications, may skew outcomes. Last, recovery surveys were not provided to pre-ERAS controls.

Summary Statement
Although high-quality evidence evaluating ERAS protocols in AlBR is limited, ERAS appears to reduce postoperative opioid use and pain with improved recovery quality. Emphasis should be applied to multimodal use of preoperative and postoperative acetaminophen, gabapentin, and/or nonsteroidal anti-inflammatory drugs (NSAIDS). These agents reduce pain and opioid use in breast and plastic surgery procedures. As recommended by the Clinical Practice Guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists’ Committee on Regional Anesthesia, Executive Committee, and Administrative Council (Recommendation 10), prophylactic preoperative opioids should not be prescribed given the lack of clear benefit derived from preoperative narcotics. Additional agents employed via ERAS pathways (ie, avoidance of prolonged fasting, scopolamine patches, etc.) are not intended to spare opioids, but are thought to improve overall patient outcomes. Intraoperative local analgesia recommendations are described below.

Paravertebral Blocks
Despite the randomized control study design, Wolf et al’s analysis may be skewed by a surgical population extending beyond immediate AlBR, incorporating delayed AlBR in addition to a large percentage (54.05%) of second stage expander-to-implant procedures with concurrent symmetrizing surgeries. Although this improves external generalizability, it introduces confounding variables. Several salient limitations are present in the additional retrospective studies evaluated. Each lacked consistent time-point recordings of pain scores. Notably, Coopey et al attempted to control for this by reporting conversion to oral opioids, a surrogate of transitioning to less severe pain. Unfortunately, they do not report mean morphine consumption. Moreover, with the exception of Aufforth et al, studies did not quantify opioid-naïvetry, CPS, and axillary procedures. Aufforth et al’s study is limited by small subgroup analyses required to identify differences in reconstructive patients’ opioid use and was confounded by a greater number of axillary procedures in the PVB cohort and lumpectomies in the non-PVB cohort. Moreover, NSAID use was uncontrolled. Finally, some studies lacked perioperative medication standardization.

Summary Statement
Level 1 evidence provided by Wolf et al, in conjunction with limited level 3 evidence, suggests that paravertebral blocks should be employed in AlBR to reduce opioid use. PVBs reduce pain scores in AlBR, but do not decrease nausea/antiemetic use. In nonreconstructive breast procedures, PVBs reduce pain and opioid consumption with reported postoperative pain relief ranging from 0.5 to 12 hours. PVBs should be considered a component of multimodal ERAS protocols.

Intercostal Blocks
Both ICB studies reduce confounding by excluding patients with CPS or chronic opioid use and employing standardized postoperative opioid regimens, yet limitations remain. One study is confounded by botulinum toxin pectoralis injections, which may underpower findings and prevents pure interpretation of ICBs. Furthermore, the unilateral nonblock cohort was somewhat underrepresented (n = 12 compared to n = 43) and the study should transparently report opioid consumption among all patients as mean morphine equivalents without laterality subgroup analysis. Lanier et al uniquely noted that 16 of 34 patients experienced significant axillary pain during recovery which suggests technical inadequacy of ICBs. A prior assessment by Blanco et al notes the importance of anesthetizing the long thoracic and thoracodorsal nerves for axillary anesthesia. Lanier et al additionally performed pectoral blocks, but noted a lack of medial pectoral nerve visualization during infusion.

Summary Statement
Conflicting outcomes exist in the studies evaluating ICBs in AlBR. The absence of higher-quality prospective studies supporting ICBs precludes recommendation to implement ICBs in favor of PVBs. Although ICBs tend to be more rapidly employed than PVBs, their opioid-sparing affect seems marginal, in part due to axillary pain.

Liposomal Bupivacaine
Results of LB appear somewhat heterogenous. Motakef et al’s randomized trial is somewhat constrained by a small sample size but is otherwise devoid of major flaws. Abdelsattar et al identified improved pain control with LB, yet did not demonstrate a difference in opioid consumption and lacked consistent time-point pain score recordings, particularly beyond 36 hours, an optimal time to elucidate the effects of LB. They did not quantify opioid naïve patients and had cohort discrepancies in submascular versus subglandular TE placement. Despite having a larger sample size, Butz et al’s study is limited as a portion of the control arm received local anesthesia, which obscured the immediate postoperative impact of LB at 0.5 and 2 hours postoperatively. Last, Butz et al neither analyze nor characterize patients with prior opioid use or CPS. Despite reporting a statistical difference in the same-day discharge, this study appears to be somewhat underpowered as HLOS, measured in hours or days, is not statistically different.
**Summary Statement**

Commercially available LB, Exparel (Pacira Pharmaceuticals; Parsippany, N.J.), is indicated for postsurgical local analgesia or for interscalene brachial plexus nerve blocks.37,38 Abdelsattar et al has previously defined an injection technique for AlBR.37 A 2016 systematic review reports safe outcomes with generally improved analgesia in several surgical procedures.39 Local intraoperative infiltration of LB is recommended as a component of ERAS pathways.

**Diclofenac**

The randomized study design and standardized perioperative medication regimen employed by Legeby et al is highly commendable with some limitations.36 The authors do not identify patients with CPS or prior opioid use. Additionally, the authors state that they adjust for unilateral versus bilateral cases; however, it is unclear if they account for the symmetrizing procedures that occurred in unilateral cases. The authors perform multivariable regression to analyze blood loss, but do not report odds ratios or factors within the regression model. Last, a 3-day stay for immediate AlBR is uncommon in the years since publication.

**Summary Statement**

Although diclofenac use reduced early opioid consumption in AlBR, it was not shown to be effective during early mobilization suggesting inefficiency as a standalone modality for pain control. Although increased perioperative bleeding was observed, meta-analyses in plastic surgery have not consistently demonstrated this risk of NSAIDs.50,59 NSAIDs remain a recommended component of AlBR ERAS pathways.

**Local Anesthesia**

Both articles evaluating LA have noted limitations. Lu and Fine38 do not describe patient histories of prior opioid use, appears to lack standardized antiemetic protocols, and does not specify patient criteria for transition from IV Dilaudid to oral hydrocodone/acetaminophen.37 Additionally, pain scores were only tracked within the PACU, limiting findings. Last, lack of conversion to mean morphine equivalents impairs opioid consumption quantification. Comparatively, Strazisar et al’s analysis is strengthened by standardized anesthesia, scheduled pain measurements, and patient exclusion for prior chronic opioid consumption.36 However, the study is significantly confounded by postoperative pain regimens. Although 3-mg rescue doses of intravenous piritramide were available to both cohorts, the control cohort received a continuous infusion of piritramide (30 mg) over 24 hours. Their subsequent mean piritramide use was 29.4 mg in 24 hours, compared to 9.8 mg in the study cohort. The control group may not have needed 29.4 mg of piritramide, but the continuous administration was predicated on study design. Subsequent comparisons are confounded. Moreover, the 5.3-day HLOS is notable.

**Summary Statement**

Although LA infusions reduced opioid consumption, the studies identified have limited and confounded methodology and outcomes. The absence of quality prospective studies supporting LA infusions precludes their recommendation in ERAS pathways. Our findings preferentially suggest PVBs and/or LB field blocks over LA infusions.

This systematic review is not without limitations. The notable paucity of patients undergoing prepectoral AlBR in this literature limits our review. Prepectoral AlBR prevents chest wall dissection, preserves the pectoralis muscle, and potentially reduces pain.60–62 Copeland-Halperin et al recently demonstrated that patients undergoing prepectoral AlBR required fewer days and refills of opioid medications than their counterparts undergoing subpectoral AlBR. Future studies assessing AlBR pain management must consider prepectoral approaches. Additionally, these recommendations are made through limited level 1 and 3 evidence. There is considerable need for additional level 1 randomized trials with appropriately designed placebo-controlled cohorts undergoing standardized perioperative management. Moreover, article bias was assessed and reported as aggregate qualitative findings by a single reviewer and the GRADE certainty of evidence was not applied, which is a deviation of our original PROSPERO protocol. Last, meta-analysis could not be performed due to outcomes heterogeneity. Future trials should adhere to uniform outcomes, particularly unadjusted mean morphine equivalent consumption.

**CONCLUSIONS**

Considerable pain accompanies AlBR. Multimodal analgesia should be provided via ERAS pathways to spare opioid use. Acetaminophen, NSAIDs, gabapentin, PVBs, and LB are essential components to ERAS protocols. Additional prospective, randomized trials are necessary to further delineate efficacy. Due to the limited quality of current literature, future trials need consistent endpoints (mean morphine equivalents utilized at specific postoperative time points), clear documentation of pain medication provided (dose and frequency), and patient demographics (including cohort exposure to radiation and history of prior opioid/narcotic use).

**ACKNOWLEDGMENTS**

We would like to thank Paul Bain, PhD, MLIS, and the Countway Medical Library at the Harvard Medical School for assisting in the development of our search strategy and in conducting our literature review.
REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34.
2. Yuch JJ, Slavin SA, Adesiyun T, et al. Patient satisfaction in post-mastectomy breast reconstruction: a comparative evaluation of DIEP, TRAM, latissimus flap, and implant techniques. Plast Reconstr Surg. 2010;125:1585–1595.
3. Qureshi AA, Odom EB, Parikh RP, et al. Patient-reported outcomes of aesthetics and satisfaction in immediate breast reconstruction after nipple-sparing mastectomy with implants and fat grafting. Aesthet Surg J. 2017;37:999–1008.
4. Hu ES, Pusic AL, Waljee JF, et al. Patient-reported aesthetic satisfaction with breast reconstruction during the long-term survivorship period. Plast Reconstr Surg. 2009;124:1–8.
5. American Society of Plastic Surgeons. 2017 Plastic Surgery Statistics Report. Plastic Surgery Statistics. 2017.
6. Legeby M, Segerdahl M, Sandelin K, et al. Immediate reconstruction in breast cancer surgery requires intensive post-operative pain treatment but the effects of axillary dissection may be more predictive of chronic pain. Breast. 2002;11:156–162.
7. Tasmuth T, Estlanderb AM, Kalso E. Effect of present pain and mood on the memory of past postoperative pain in women treated surgically for breast cancer. Pain. 1996;68:343–347.
8. Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: risk factors and prevention. Lancet. 2006;367:1618–1625.
9. Johom G, Abdalla H, O’Brien J, et al. The associations between severity of early postoperative pain, chronic postoperative pain and plasma concentration of stable nitric oxide products after breast surgery. Anesth Analg. 2006;103:995–1000.
10. Hickey OT, Burke SM, Hafeez P, et al. Severity of acute pain after breast surgery is associated with the likelihood of subsequently developing persistent pain. J Pain. 2010;26:556–560.
11. Poloehack EL, Katz J, Andrus CH, et al. Risk factors for chronic pain following breast cancer surgery: a prospective study. J Pain. 2006;7:626–634.
12. Shah A, Rowlands M, Krishnan N, et al. Thoracic intercostal nerve blocks reduce opioid consumption and length of stay in patients undergoing implant-based breast reconstruction. Plast Reconstr Surg. 2015;136:584e–591e.
13. Hoppe IC, Stanley SS, Ciminello FS. Pain control following breast augmentation: a qualitative systematic review. Aesthet Surg J. 2019;39:964–972.
14. Crystal DT, Blankensteijn LL, Ibrahim AMS, et al. Quantifying the crisis: opioid-related adverse events in outpatient ambulatory plastic surgery. Plast Reconstr Surg. 2020;145:687–695.
15. Bennett KG, Kelley BP, Vick AD, et al. Persistent opioid use and high-risk prescribing in body contouring patients. Plast Reconstr Surg. 2019;143:87–96.
16. Marcus DP, Mann RA, Cron DC, et al. Prescription opioid use among opioid-naive women undergoing immediate breast reconstruction. Plast Reconstr Surg. 2017;140:1081–1090.
17. Hart AM, Broecker JS, Kao L, et al. Opioid use following outpatient breast surgery: are physicians part of the problem? Plast Reconstr Surg. 2018;142:611–620.
18. Rogers J, Cunningham K, Fitzgerald K, et al. Opioid consumption following outpatient upper extremity surgery. J Hand Surg Am. 2012;37:645–650.
19. Rose KR, Christie BM, Block LM, et al. Opioid prescribing and consumption patterns following outpatient plastic surgery procedures. Plast Reconstr Surg. 2019;143:929–938.
20. Patel S, Sturm A, Bohian M, et al. Opioid use by patients after rhinoplasty. JAMA Facial Plast Surg. 2018;20:24–30.
21. Chu JJ, Janis JE, Skoracki R, et al. Opioid overprescribing and procedure-specific opioid consumption patterns for plastic and reconstructive surgery patients. Plast Reconstr Surg. 2021;147:669e–679e.
22. Redfield RR. CDC Director’s Media Statement on U.S. Life Expectancy. Washington, D.C.: CDC Newsroom Releases; 2018.
23. Crystal D, Blankensteijn L, Cucco N, et al. Effectiveness of opioid sparing versus non-opioid sparing pain management strategies in patients undergoing breast reconstruction. PROSPERO International Prospective Register of Systematic Reviews. 2018.
24. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.
25. Moher D, Liberati A, Tetzlaff J, et al; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
26. Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4319.
27. Chiu C, Alesh P, Esserman LJ, et al. Improved analgesia and reduced post-operative nausea and vomiting after implementation of an enhanced recovery after surgery (ERAS) pathway for total mastectomy. BMC Anesthesiol. 2018;18:41.
28. Dumestre DO, Webb CE, Temple-Oberle C. Improved recovery experience achieved for women undergoing implant-based breast reconstruction using an enhanced recovery after surgery model. Plast Reconstr Surg. 2017;139:550–559.
29. Lanier ST, Lewis KG, Kendall MC, et al. Intraoperative nerve blocks fail to improve quality of recovery after tissue expander breast reconstruction: a prospective, double-blinded, randomized, placebo-controlled clinical trial. Plast Reconstr Surg. 2018;141:590–597.
30. Wolf O, Clemens MW, Purugganan RV, et al. A prospective, randomized, controlled trial of paravertebral block versus general anesthesia alone for prosthetic breast reconstruction. Plast Reconstr Surg. 2016;137:660e–666e.
31. Fahy AS, Jakub JW, Dy BM, et al. Paravertebral blocks in patients undergoing mastectomy with or without immediate reconstruction provides improved pain control and decreased postoperative nausea and vomiting. Ann Surg Oncol. 2014;21:3284–3289.
32. Coopey SB, Specht MC, Warren L, et al. Use of preoperative paravertebral block decreases length of stay in patients undergoing mastectomy plus immediate reconstruction. Ann Surg Oncol. 2013;20:1282–1286.
33. Auffarth R, Jain J, Morreale J, et al. Paravertebral blocks in breast cancer surgery: is there a difference in postoperative pain, nausea, and vomiting? Ann Surg Oncol. 2012;19:548–552.
34. Abdelsattar JM, Bourghay CJ, Fahy AS, et al. Comparative study of liposomal bupivacaine versus paravertebral block for pain control following mastectomy with immediate tissue expander reconstruction. Ann Surg Oncol. 2016;23:465–470.
35. Motakef S, Wong WW, Ingargiola MJ, et al. Liposomal bupivacaine in implant-based breast reconstruction. Plast Reconstr Surg Glob Open. 2017;5:e1559.
36. Butz DR, Shenaq DS, Rundell VL, et al. Postoperative pain and length of stay lowered by use of exarel in immediate, implant-based breast reconstruction. Plast Reconstr Surg Glob Open. 2015;3:e391.
37. Legeby M, Sandelin K, Wickman M, et al. Analgesic efficacy of diclofenac in combination with morphine and paracetamol after mastectomy and immediate breast reconstruction. Acta Anaesthesiol Scand. 2005;49:1360–1366.
38. Lu L, Fine NA. The efficacy of continuous local anesthetic infiltration in breast surgery: reduction mammaplasty and reconstruction. Plast Reconstr Surg. 2005;115:1927–1934; discussion 1935.
39. Strazisar B, Besic N, Ahcan U. Does a continuous local anaesthetic pain treatment after immediate tissue expander reconstruction
in breast carcinoma patients more efficiently reduce acute postoperative pain—a prospective randomised study. *World J Surg Oncol.* 2014;12:16.

40. Abdelsattar JM, Degnim AC, Hieken TJ, et al. Local infiltration of liposomal bupivacaine for pain control in patients undergoing mastectomy with immediate tissue expander reconstruction. *Ann Surg Oncol.* 2015;22:3402–3403.

41. Nissen MJ, Swenson KK, Ritz LJ, et al. Quality of life after breast carcinoma surgery: a comparison of three surgical procedures. *Cancer.* 2001;91:1238–1246.

42. Weinheimer K, Michelotti B, Silver J, et al. A prospective, randomized, double-blinded controlled trial comparing ibuprofen and acetaminophen versus hydrocodone and acetaminophen for soft tissue hand procedures. *J Hand Surg Am.* 2019;44:387–393.

43. Johnson SP, Wormer BA, Silvestrini R, et al. Reducing opioid prescribing after ambulatory plastic surgery with an opioid-restrictive pain protocol. *Ann Plast Surg.* 2020;84(6 suppl 5):S431–S436.

44. Mitchell A, McCrea P, Inglis K, et al. A randomized, double-blinded controlled trial comparing acetaminophen plus ibuprofen versus acetaminophen plus codeine plus caffeine (Tylenol 3) after outpatient breast surgery. *Ann Surg Oncol.* 2012;19:3792–3800.

45. Barker JC, DiBartola K, Wey C, et al. Preoperative multimodal analgesia decreases postanesthesia care unit narcotic use and pain scores in outpatient breast surgery. *Plast Reconstr Surg.* 2018;142:443e–450e.

46. Yan C, Wink JD, Ligh CA, et al. The effects of adjunctive pain medications on postoperative inpatient opioid use in abdominally based microsurgical breast reconstruction. *Ann Plast Surg.* 2020;85:e3–e6.

47. Parsa AA, Sprouse-Blum AS, Jackowe DJ, et al. Combined preoperative use of celecoxib and gabapentin in the management of postoperative pain. *Aesthetic Plast Surg.* 2009;33:98–103.

48. Fan KL, Luvisa K, Black CK, et al. Gabapentin decreases narcotic usage: enhanced recovery after surgery pathway in free autologous breast reconstruction. *Plast Reconstr Surg Glob Open.* 2019;7:e2550.

49. Rai AS, Khan JS, Dhillon J, et al. Preoperative pregabalin or gabapentin for acute and chronic postoperative pain among patients undergoing breast cancer surgery: a systematic review and meta-analysis of randomized controlled trials. *J Plast Reconstr Aesthet Surg.* 2017;70:1317–1328.

50. Kelley BP, Bennett KG, Chung KC, et al. Ibuprofen may not increase bleeding risk in plastic surgery: A systematic review and meta-analysis. *Plast Reconstr Surg.* 2016;137:1309–1316.

51. Chou R, Gordon DB, de Leon-Casasola OA, et al. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists’ Committee on Regional Anesthesia, Executive Committee, and Administrative Council. *J Pain.* 2016;17:131–157.

52. Moller JF, Nikolajsen L, Rødt SA, et al. Thoracic paravertebral block for breast cancer surgery: a randomized double-blind study. *Anesth Analg.* 2007;105:1848–51, table of contents.

53. Terheggen MA, Wille F, Borel Rinkes IH, et al. Paravertebral blockade for minor breast surgery. *Anesth Analg.* 2002;94:355–359, table of contents.

54. Pusch F, Freitag H, Weinstabl C, et al. Single-injection paravertebral block compared to general anaesthesia in breast surgery. *Acta Anaesthesiol Scand.* 1999;43:770–774.

55. Kairoluoma PM, Bachmann MS, Korpinen AK, et al. Single-injection paravertebral block before general anesthesia enhances analgesia after breast cancer surgery with and without associated lymph node biopsy. *Anesth Analg.* 2004;99:1837–1843.

56. Blanco R, Fajardo M, Parras Maldonado T. Ultrasound description of Pecs II (modified Pecs I): a novel approach to breast surgery. *Rev Esp Anestesiol Reanim.* 2012;59:470–475.

57. Pacira Pharmaceuticals I. Full prescribing information. 2018.

58. Vyas KS, Rajendra S, Morrison SD, et al. Systematic review of liposomal bupivacaine (Exparel) for postoperative analgesia. *Plast Reconstr Surg.* 2016;138:748e–756e.

59. Walker NJ, Jones VM, Kratky L, et al. Hematoma risks of nonsteroidal anti-inflammatory drugs used in plastic surgery procedures: a systematic review and meta-analysis. *Ann Plast Surg.* 2019;82(6 suppl 5):S437–S445.

60. Shibany H, Piper M, Lenz R. Prepectoral breast reconstruction: a safe alternative to submuscular prosthetic reconstruction following nipple-sparing mastectomy. *Plast Reconstr Surg.* 2017;140(6 Suppl 5):S431–S436.

61. Shibany H, Pip P, Lenz R. Prepectoral breast reconstruction: a safe alternative to submuscular prosthetic reconstruction following nipple-sparing mastectomy. *Plast Reconstr Surg.* 2017;140:432–443.

62. Sigalove S, Maxwell GP, Sigalove NM, et al. Prepectoral implant-based breast reconstruction: rationale, indications, and preliminary results. *Plast Reconstr Surg.* 2017;139:287–294.

63. Copeland-Halperin LR, Yemch L, Emery E, et al. Evaluating postoperative narcotic use in prepectoral versus dual-plane breast reconstruction following mastectomy. *Plast Reconstr Surg Glob Open.* 2019;7:e2082.